Andelyn Biosciences, Inc., a leading cell and gene therapy contract development and manufacturing organization (CDMO), has announced a strategic partnership with Amplo Biotechnology to advance gene therapy programs targeting neuromuscular junction (NMJ) disorders. The collaboration will leverage Andelyn’s suspension AAV Curator platform to manufacture scalable, clinical-grade adeno-associated virus (AAV) material.

NMJ disorders often cause severe muscle weakness, with many patients requiring respiratory support, wheelchairs, or tube feeding. These genetic diseases can be life-threatening, often diagnosed in childhood but sometimes appearing later in life.

Andelyn’s Curator platform provides a highly characterized, data-driven, and scalable AAV process designed to streamline the path to cGMP and commercial manufacturing. Through this platform, Amplo aims to accelerate its AAV gene therapy pipeline into clinical trials with a focus on safety and efficacy.

“As a clinical and commercial CDMO, we are honored to support Amplo Biotechnology’s mission of bringing hope to patients with debilitating NMJ diseases,” said Matt Niloff, chief commercial officer, Andelyn Biosciences. “Our Curator platform and end-to-end expertise are built to help partners achieve key development milestones.”

The partnership enhances Amplo’s ability to deliver high-quality AAV material while aligning with its mission to develop transformative therapies for families worldwide. Together, both companies aim to push the boundaries of gene therapy innovation and bring meaningful treatments closer to patients in need.